USFDA1 Sept 2026, 03:50 pm
Gland Pharma USFDA Inspection Concludes with Zero Observations
AI Summary
Gland Pharma Ltd announced the conclusion of a routine USFDA Good Manufacturing Practice (GMP) Inspection at its Visakhapatnam facilities, specifically the VSEZ Sterile Oncology Formulations Facility and API Facility. The inspection, conducted between August 24, 2026, and September 01, 2026, resulted in zero Form 483 observations. This outcome is a positive indicator of the company's compliance with international regulatory standards, potentially bolstering investor confidence and ensuring continued market access for its products.
Key Highlights
- USFDA inspection at Visakhapatnam facilities concluded.
- Inspection resulted in zero Form 483 observations.
- Positive regulatory compliance outcome.
- Reinforces manufacturing standards and quality control.
Price Impact
More from GLAND